3.45亿元！鹿得医疗最新年报

Core Viewpoint - The company, Jiangsu Lude Medical Electronics Co., Ltd., reported a revenue increase of 4.66% in 2024, but experienced a decline in net profit by 13.08%, indicating challenges in profitability despite revenue growth [1][2]. Financial Performance - The company achieved operating revenue of 344.60 million in 2024, up from 329.26 million in 2023, reflecting a growth of 4.66% [1][2]. - The net profit attributable to shareholders was 27.54 million, down 13.08% from 31.69 million in the previous year [1][2]. - The net profit after deducting non-recurring gains and losses was 26.21 million, a decrease of 12.64% compared to 30.00 million in 2023 [1][2]. - The weighted average return on equity based on net profit attributable to shareholders was 7.00%, down from 8.19% in 2023 [1]. - Basic earnings per share decreased to 0.16 from 0.18, reflecting a decline of 13.08% [1]. Business Overview - Jiangsu Lude Medical focuses on the research, development, production, and sales of home medical devices and healthcare products [5]. - The company has been listed on the Beijing Stock Exchange since November 15, 2021, after being one of the first 32 companies to go public on the selected tier [5]. - The main product categories include home medical devices such as blood pressure monitors, nebulizers, and thermometers, as well as healthcare products related to family health management [6]. Cash Flow and Assets - The net cash flow from operating activities was 13.03 million, showing a significant decline of 61.70% year-on-year [5]. - As of the end of 2024, total assets amounted to 530 million, an increase of 7.94% compared to the previous year [5]. - The equity attributable to shareholders was 400 million, reflecting a growth of 2.61% [5]. Research and Development - The company continued to invest in research and development, with R&D expenses increasing by 4.33% in 2024, aimed at product innovation and technological upgrades [5]. Market Expansion - The company actively expanded its overseas market presence, achieving significant sales growth through cross-border e-commerce platforms [5]. - In 2024, several products received EU MDR CE certification and MDSAP certification, enhancing competitiveness in international markets [5].